Show simple item record

dc.creatorBlass, Benjamin E.
dc.creatorPuri, Sumant
dc.creatorSharma, Rishabh
dc.creatorDay, Brian M.
dc.date.accessioned2024-03-13T20:24:00Z
dc.date.available2024-03-13T20:24:00Z
dc.date.issued2022-08-29
dc.identifier.citationBlass BE, Puri S, Sharma R and Day BM (2022) Antifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs. Front. Drug. Discov. 2:1000827. doi: 10.3389/fddsv.2022.1000827
dc.identifier.issn2674-0338
dc.identifier.urihttp://hdl.handle.net/20.500.12613/9897
dc.description.abstractInvasive candidiasis remains a significant health concern, as it is associated with a high mortality risk. In addition, the risk of infection is significantly elevated in immunocompromised patients such as those with HIV, cancer, or those taking imcmunosuppressive drugs as a result of organ transplantation. The majority of these cases are caused by C. albicans, and C. glabrata is the second most common cause. These infections are typically treated using approved antifungal agents, but the rise of drug-resistant fungi is a serious concern. As part of our on-going effort to identify novel antifungal agents, we have studied the in vitro antifungal properties of a series of sulfonamide analogs of (2S, 4R)-Ketoconazole. Herein we report on the in vitro activity against the key fungal pathogens C. albicans, and C. glabrata.
dc.format.extent6 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartFrontiers in Drug Discovery
dc.relation.isreferencedbyFrontiers Media
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAntifungal agent
dc.subjectAntimicrobial agents
dc.subjectKetoconazole
dc.subjectCandida albicans
dc.subjectCandida glabrata
dc.titleAntifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs
dc.typeText
dc.type.genreJournal article
dc.contributor.groupOral Microbiome Research Laboratory (Temple University)
dc.description.departmentPharmaceutical Sciences
dc.relation.doihttp://dx.doi.org/10.3389/fddsv.2022.1000827
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeTemple University. School of Pharmacy
dc.description.schoolcollegeKornberg School of Dentistry
dc.creator.orcidPuri|0000-0002-5509-007X
dc.temple.creatorBlass, Benjamin E.
dc.temple.creatorPuri, Sumant
dc.temple.creatorSharma, Rishabh
dc.temple.creatorDay, Brian M.
refterms.dateFOA2024-03-13T20:24:00Z


Files in this item

Thumbnail
Name:
BlassEtAl-JournalArticle-2022- ...
Size:
733.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY